Estudio primario
No clasificado
Este artículo está incluido en 1 Síntesis amplia Síntesis amplias (1 referencia)
Estudio primario
No clasificado
Este artículo está incluido en 1 Síntesis amplia Síntesis amplias (1 referencia)
The prior diagnosis of fatal astrocytoma in a 60-year-old man with Crohn's disease treated with natalizumab, a monoclonal antibody against alpha4 integrins, was reclassified as JC virus-related progressive multifocal leukoencephalopathy (PML). Analysis of frozen serum samples showed that JC virus DNA had appeared in the serum three months after the initiation of open-label natalizumab monotherapy and two months before the appearance of symptomatic PML. There was staining of the brain lesion for polyomavirus. This case report, along with two others, suggests that anti-alpha4-integrin therapy can result in JC virus-induced PML.
Resumen estructurado de revisiones sistemáticas
No clasificado
Estudio primario
No clasificado
Este artículo está incluido en 3 Revisiones sistemáticas Revisiones sistemáticas (3 referencias)
Estudio primario
No clasificado
Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)
Estudio primario
No clasificado
Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)
Estudio primario
No clasificado
Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)
Resumen estructurado de revisiones sistemáticas
No clasificado
Este artículo incluye 1 Revisión sistemática Revisiones sistemáticas (1 referencia)
Este artículo no tiene resumen
Resumen estructurado de revisiones sistemáticas
No clasificado
Estudio primario
No clasificado
Este artículo está incluido en 2 Revisiones sistemáticas Revisiones sistemáticas (2 referencias)
The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNβ)-1a in patients with relapsing multiple sclerosis (MS). Further analyses of AFFIRM and SENTINEL data were conducted to determine the efficacy of natalizumab in prespecified patient subgroups according to baseline characteristics: relapse history 1 year before randomization (1, 2, 3), Expanded Disability Status Scale score (3.5, > 3.5), number of T2 lesions (< 9, 9), presence of gadolinium-enhancing (Gd+) lesions (0, 1), age (< 40, 40) and gender (male, female). A post hoc analysis was conducted to determine the efficacy of natalizumab in patients with highly active disease (i. e., 2 relapses in the year before study entry and 1 Gd+ lesion at study entry). In both AFFIRM and SENTINEL studies natalizumab reduced the annualized relapse rates across all subgroups (except the small subgroups with < 9 baseline T2 lesions) over 2 years. In AFFIRM, natalizumab significantly reduced the risk of sustained disability progression in most subgroups. In SENTINEL, natalizumab significantly reduced the risk of sustained disability progression in the following subgroups: 9 T2 lesions at baseline, 1 Gd+ lesions at baseline, female patients and patients < 40 years of age. Natalizumab reduced the risk of disability progression by 64 % and relapse rate by 81 % in treatment- naive patients with highly active disease and by 58 % and 76 %, respectively, in patients with highly active disease despite IFNβ-1a treatment. These results indicate that natalizumab is effective in reducing disability progres- sion and relapses in patients with relapsing MS, particularly in patients with highly active disease. © 2009 Steinkopff-Verlag.